PURPOSE: To assess the clinical and pathologic significance of mast cell infiltration in human pancreatic cancer and evaluate crosstalk between mast cells and cancer cells in vitro. EXPERIMENTAL DESIGN: Immunohistochemistry for tryptase was done on 53 pancreatic cancer specimens. Mast cell counts were correlated with clinical variables and survival. Serum tryptase activity from patients with cancer was compared with patients with benign pancreatic disease. In vitro, the effect of pancreatic cancer-conditioned medium on mast cell migration was assessed. The effect of conditioned medium from the human mast cell line, LAD-2, on cancer and normal ductal cell proliferation was assessed by thymidine incorporation. Matrigel invasion assays were used to evaluate the effect of mast cell-conditioned medium on cancer cell invasion in the presence and absence of a matrix metalloproteinase inhibitor, GM6001. RESULTS: Mast cell infiltration was significantly increased in pancreatic cancer compared with normal pancreatic tissue (11.4 +/- 6.7 versus 2.0 +/- 1.4, P < 0.001). Increased infiltrating mast cells correlated with higher grade tumors (P < 0.0001) and worse survival. Patients with pancreatic cancer had elevated serum tryptase activity (P < 0.05). In vitro, AsPC1 and PANC-1 cells induced mast cell migration. Mast cell-conditioned medium induced pancreatic cancer cell migration, proliferation, and invasion but had no effect on normal ductal cells. Furthermore, the effect of mast cells on cancer cell invasion was, in large part, matrix metalloproteinase-dependent. CONCLUSIONS: Tumor-infiltrating mast cells are associated with worse prognosis in pancreatic cancer. In vitro, the interaction between mast cells and pancreatic cancer cells promotes tumor growth and invasion.
PURPOSE: To assess the clinical and pathologic significance of mast cell infiltration in humanpancreatic cancer and evaluate crosstalk between mast cells and cancer cells in vitro. EXPERIMENTAL DESIGN: Immunohistochemistry for tryptase was done on 53 pancreatic cancer specimens. Mast cell counts were correlated with clinical variables and survival. Serum tryptase activity from patients with cancer was compared with patients with benign pancreatic disease. In vitro, the effect of pancreatic cancer-conditioned medium on mast cell migration was assessed. The effect of conditioned medium from the human mast cell line, LAD-2, on cancer and normal ductal cell proliferation was assessed by thymidine incorporation. Matrigel invasion assays were used to evaluate the effect of mast cell-conditioned medium on cancer cell invasion in the presence and absence of a matrix metalloproteinase inhibitor, GM6001. RESULTS: Mast cell infiltration was significantly increased in pancreatic cancer compared with normal pancreatic tissue (11.4 +/- 6.7 versus 2.0 +/- 1.4, P < 0.001). Increased infiltrating mast cells correlated with higher grade tumors (P < 0.0001) and worse survival. Patients with pancreatic cancer had elevated serum tryptase activity (P < 0.05). In vitro, AsPC1 and PANC-1 cells induced mast cell migration. Mast cell-conditioned medium induced pancreatic cancer cell migration, proliferation, and invasion but had no effect on normal ductal cells. Furthermore, the effect of mast cells on cancer cell invasion was, in large part, matrix metalloproteinase-dependent. CONCLUSIONS:Tumor-infiltrating mast cells are associated with worse prognosis in pancreatic cancer. In vitro, the interaction between mast cells and pancreatic cancer cells promotes tumor growth and invasion.
Authors: Pio Conti; Maria L Castellani; Durasamy Kempuraj; Vincenzo Salini; Jacopo Vecchiet; Stefano Tetè; Filiberto Mastrangelo; Alessandro Perrella; Maria Anna De Lutiis; Michael Tagen; Theoharis C Theoharides Journal: Ann Clin Lab Sci Date: 2007 Impact factor: 1.256
Authors: N Nonomura; H Takayama; K Nishimura; D Oka; Y Nakai; M Shiba; A Tsujimura; M Nakayama; K Aozasa; A Okuyama Journal: Br J Cancer Date: 2007-09-11 Impact factor: 7.640
Authors: David Z Chang; Ying Ma; Baoan Ji; Huamin Wang; Defeng Deng; Yan Liu; James L Abbruzzese; Yong-jun Liu; Craig D Logsdon; Patrick Hwu Journal: Clin Cancer Res Date: 2011-10-05 Impact factor: 12.531
Authors: Eric C Cheon; Matthew J Strouch; Morgan R Barron; Yongzeng Ding; Laleh G Melstrom; Seth B Krantz; Bhargava Mullapudi; Kevin Adrian; Sambasiva Rao; Thomas E Adrian; David J Bentrem; Paul J Grippo Journal: Int J Cancer Date: 2010-10-26 Impact factor: 7.396
Authors: Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek Journal: Cancer Res Date: 2015-04-15 Impact factor: 12.701
Authors: Jelena Põlajeva; Tobias Bergström; Per-Henrik Edqvist; Anders Lundequist; Anna Sjösten; Gunnar Nilsson; Anja Smits; Michael Bergqvist; Fredrik Pontén; Bengt Westermark; Gunnar Pejler; Karin Forsberg Nilsson; Elena Tchougounova Journal: Mol Oncol Date: 2013-09-18 Impact factor: 6.603
Authors: Mohammad W Khan; Ali Keshavarzian; Elias Gounaris; Joshua E Melson; Eric C Cheon; Nichole R Blatner; Zongmin E Chen; Fu-Nien Tsai; Goo Lee; Hyunji Ryu; Terrence A Barrett; David J Bentrem; Philipp Beckhove; Khashayarsha Khazaie Journal: Clin Cancer Res Date: 2013-03-13 Impact factor: 12.531